RxDoctor Payments Data

Joanna Edwards, MD

Family Medicine · Deltona, FLNPI 1558791434

Payments from drug & device makers

$3,870in general payments, 2019–2025

Across 187 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$366
  • Johnson & Johnson$351
  • Alkermes, Inc.$297
  • Lundbeck LLC$185
  • Vanda Pharmaceuticals Inc.$158
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,867100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,870 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$14,855
Medicare patients
45
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide24$32,223
UbrelvyUbrogepant13$21,607
Nurtec OdtRimegepant Sulfate11$21,092
OzempicSemaglutide17$19,855
QuliptaAtogepant14$15,383
JardianceEmpagliflozin11$12,957
MyrbetriqMirabegron11$6,898
Lidocaine12$2,979
SynthroidLevothyroxine Sodium20$2,416
Rosuvastatin Calcium68$1,351
Trifluoperazine Hcl12$1,004
Diclofenac Sodium18$988
Atorvastatin Calcium78$780
Mirtazapine27$719
Celecoxib20$699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Synthroid$1,221$39,40647 claims
Lilly USA, LLCMounjaro$122$32,22324 claims
PfizerNurtec Odt$140$21,09211 claims
Novo NordiskOzempic$136$19,85517 claims
Boehringer IngelheimJardiance$60$12,95711 claims
Astellas Pharma US IncMyrbetriq$20$6,89811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Deltona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →